Clinical Trials in North Carolina

Showing 15741-15760 of 20,428 trials

Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders

NCT02120300

The primary objectives of this study are to evaluate the antiviral efficacy, safety, and tolerability of treatment with ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) in participants with genotypes 1 and 4 hepatitis C virus (HCV) infection and sofosbuvir (SOF) plus ribavirin (RBV) in participants with genotypes 2 and 3 HCV infection. Participants with an inherited bleeding disorder and chronic HCV infection (either monoinfected or HIV-1/HCV coinfected) will be enrolled.

Chronic HCV Infection

Gilead Sciences122 participantsStarted Apr 2014

Sacramento, California, United States • San Diego, California, United States • San Francisco, California, United States +10 more locations

COMPLETEDPhase 346 miles

Study Evaluating LAMICTAL Extended-Release Therapy Added To Current Seizure Treatments In Patients With Partial Seizures

NCT00113165

This study is being conducted to compare the efficacy and safety of LAMICTAL (lamotrigine) extended-release with placebo in the treatment of partial seizures. LAMICTAL extended-release is an investigational drug. Placebo tablets look like LAMICTAL extended-release tablets but do not contain active medication. In this study, LAMICTAL extended-release or placebo tablets will be added to current seizure treatments.

EpilepsyEpilepsy, Partial

GlaxoSmithKline244 participantsStarted Oct 2004

Anniston, Alabama, United States • Birmingham, Alabama, United States • Northport, Alabama, United States +145 more locations

Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders

Study Evaluating LAMICTAL Extended-Release Therapy Added To Current Seizure Treatments In Patients With Partial Seizures

Find Trials by Condition in North Carolina

Tipranavir Expanded Access Program (EAP) in PI-experienced Patients With HIV-1 Infection

Dose Proportionality of TFV-DP After a Single Dose of GS-7340 in Women

Safety and Efficacy Study of Single Doses of TT-034 in Patients With Chronic Hepatitis C

Ixabepilone + Carboplatin Metastatic Breast Cancer

Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function

Stimulant Abuser Groups to Engage in 12-Step

Effectiveness of Lumbar Fusion When NanOss Bioactive Is Used With Posterolateral Gutter Fusions

Using Stories to Address Disparities in Hypertension

Combination Chemotherapy With or Without Filgrastim in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer

Assessment of Catheter-based Interrogation and Standard Techniques for Fractional Flow Reserve Measurement

Gemcitabine Plus Docetaxel in Treating Patients With Unresectable or Metastatic Liver Cancer

Pemetrexed Disodium Plus Gemcitabine in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

LY231514 Plus Gemcitabine in Treating Women With Metastatic Breast Cancer

Docetaxel and Carboplatin in Treating Women With Metastatic Breast Cancer

Pharmacodynamic Study of the Effect of INCB013739 on Insulin Sensitivity in Obese, Type 2 Diabetic Subjects

An Open Label Safety Study of Tipranavir Co-administered With Low-dose Ritonavir in Patients With Advanced HIV-1 Infection and Limited Treatment Options.

Efficacy and Safety of Ciclesonide Administered With or Without Different Spacers in Patients With Asthma (12 to 75 y) (BY9010/M1-145)

Efficacy of Ciclesonide vs Fixed Combination of Fluticasone Propionate/Salmeterol vs Placebo in Patients With Mild Persistent Asthma (12 to 75 y) (BY9010/M1-132)